TITLE

Candesartan prevented development of diabetes mellitus in heart failure: COMMENTARY

AUTHOR(S)
Gutknecht, David R.
PUB. DATE
January 2006
SOURCE
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p11
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article comments on a clinical study according to which type 2 diabetes, which is closely linked to obesity and cardiovascular disease, may be preventable through weight control, lifestyle changes, and the use of such drugs as metformin and thiazolidinediones. The authors of the study did a preplanned subgroup analysis of data from 3 parallel placebo-controlled trials with varying inclusion criteria. Patients had different levels of LVEF, but all had symptomatic heart failure. Diabetes was most convincingly prevented in patients with preserved systolic function, with little benefit observed in those already receiving an ACE inhibitor. The overall 21% relative risk reduction is similar to that reported in other trials, involving almost 40,000 patients.
ACCESSION #
19515994

 

Related Articles

  • Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Matsuzaki, Masunori; Hori, Masatsugu; Izumi, Tohru; Asanoi, Hidetsugu; Tsutamoto, Takayoshi // Cardiovascular Drugs & Therapy;Dec2011 Supplement 1, Vol. 25, p19 

    Purpose: Tolvaptan may reduce the signs of volume overload in heart failure (HF) patients who experience volume overload despite using conventional diuretics. In this study, we evaluated the dose-response effects of tolvaptan on weight loss, urine volume and electrolyte excretion in...

  • In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events. Dans, Antonio L.; Koon Teo; Gao, Peggy; Jyh-Hong Chen; Kim Jae-Hyung; Yusoff, Khalid; Chaitraphan, Suphachai; Zhu, Jun; Liu Lisheng; Yusuf, Salim // PLoS Clinical Trials;Dec2010, Vol. 7 Issue 12, Special section p1 

    Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/ day) in reducing cardiovascular events. Clinicians in Asia...

  • ORLISTAT FOR WEIGHT LOSS MAINTENANCE.  // Pulse;5/3/2007, Vol. 67 Issue 17, p42 

    The article focuses on the effect of long-term orlistat in weight loss maintenance among the patients in Great Britain. Study shows that patients weighed between 75 kilogram and 162 kilogram had one or more cardiac risk factors. It was found out that orlistat patients weighed an average 9.4...

  • Lisinopril/hydrochlorothiazide.  // Reactions Weekly;May2014, Vol. 1500 Issue 1, p25 

    An abstract of the article "Intraoperative cardiac arrest: Was it the ACE inhibitor?," by J. Bjerregaard and colleagues is presented.

  • ACE inhibitors can prevent diabetes and heart failure.  // GP: General Practitioner;3/24/2003, p17 

    According to the results of a trial the angiotensin converting enzyme (ACE) inhibitors could prevent heart failure (HF) among patients at high risk of cardiovascular events. The ‘Heart Outcomes Prevention Evaluation’ (HOPE) study found ramipril cut the development rate of HF among...

  • Hypertension: Which drugs to choose for patients with cardiovascular disease. Wexler, Randy; Feldman, David // Journal of Family Practice;Apr2006, Vol. 55 Issue 4, p291 

    The article presents recommendations for treating patients with cardiovascular diseases such as heart failure, coronary artery disease and stroke. Hypertension is linked to heart failure cases, heart attacks and first-time strokes. A study was conducted that aims to identify a drug that will...

  • Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity. Smith, Steve R.; Aronne, Louis J.; Burns, Colleen M.; Kesty, Nicole C.; Halseth, Amy E.; Weyer, Christian // Diabetes Care;Sep2008, Vol. 31 Issue 9, p1816 

    OBJECTIVE -- To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI). RESEARCH DESIGN AND METHODS-- In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were...

  • First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Venditti, E. M.; Bray, G. A.; Carrion-Petersen, M. L.; Delahanty, L. M.; Edelstein, S. L.; Hamman, R. F.; Hoskin, M. A.; Knowler, W. C.; Ma., Y. // International Journal of Obesity;Oct2008, Vol. 32 Issue 10, p1537 

    Objective:Following unblinding of the Diabetes Prevention Program (DPP) results, a 16-session lifestyle intervention program was offered to all study participants, including those who had initially been randomized to lifestyle treatment. This study compares the effects of the lifestyle program...

  • An Apple a Day... TAKHTEHCHIAN, BAHAR // Shape;Jul/Aug2013, p141 

    The article discusses Doctor Lori Mosca's healthy lifestyle as a prevention method against cardiovascular disease, which is a common disease. Topics include lack of awareness about heart disease among women, eating vegetables and fruits to lower risks of cardiac arrest, and Mosca suggestion on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics